By: IPP Bureau
Last updated : April 01, 2024 5:54 pm
The company had earlier announced about the approval received from the MHRA for Liraglutide
Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.
The company had earlier announced about the approval received from the MHRA for Liraglutide (gVicotza), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.
The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.